Log in to save to my catalogue

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcino...

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcino...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4332724

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

About this item

Full title

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

Publisher

England: BioMed Central Ltd

Journal title

Journal of translational medicine, 2015-02, Vol.13 (1), p.57-57, Article 57

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Regorafenib, a multi-kinase inhibitor, is used in the treatment of patients with metastatic colorectal cancer refractory to standard therapy. However, this benefit was limited to 1.4 months improvement in overall survival, with more than half of patients experiencing grade 3 to 4 adverse events. We aim to elucidate the pharmacodynamic effects of re...

Alternative Titles

Full title

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4332724

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4332724

Other Identifiers

ISSN

1479-5876

E-ISSN

1479-5876

DOI

10.1186/s12967-015-0405-4

How to access this item